Targeting a specific protein to treat acute myeloid leukemia
Membrane protein target for leukemia therapy
This study is looking at a protein called DPP4 to see how it influences the growth of leukemia stem cells in people with acute myeloid leukemia (AML), and it hopes to find out if blocking DPP4 can help improve treatment outcomes for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10884500 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called DPP4 in the development of acute myeloid leukemia (AML). The study aims to understand how DPP4 affects the survival and growth of leukemia stem cells, which are crucial for the disease's progression. By using both laboratory models and patient data, the researchers will explore whether inhibiting DPP4 can lead to better outcomes for AML patients. The approach includes examining the effects of DPP4 inhibitors on leukemia cells and their ability to prevent the disease's development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those with high-risk features.
Not a fit: Patients with other types of leukemia or those who do not have AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target and eliminate leukemia stem cells, improving survival rates for AML patients.
How similar studies have performed: Preliminary studies have shown promising results with DPP4 inhibitors in laboratory settings, indicating potential for success in this approach.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Kang, Xunlei — University of Missouri-Columbia
- Study coordinator: Kang, Xunlei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.